CG Oncology, Inc. (CGON)
64.62
0.00 (0.00%)

64.62
0.00 (0.00%)
CG Oncology, Inc., kechki bosqichdagi klinik biofarmatsevtika kompaniyasi, Qo'shma Shtatlardagi siydik pufagi saratoni bilan og'rigan bemorlar uchun kreto'stimogen grenadenorepvecni ishlab chiqadi va tijoratlashtiradi. Kompaniyaning mahsulot nomzodi kreto'stimogen, tadqiq qilinayotgan onkolitik immunoterapiya, u BCG muvaffaqiyatsizligi natijasida yuqori xavfli NMIBC bemorlarida kreto'stimogenning 2-bosqich klinik sinovlarida; BCG bilan bog'liq bo'lmagan, CISni o'z ichiga olgan NMIBC va BCGga chidamsiz Ta yoki T1 papillyar o'smalarida; 3-bosqich BOND-003 C kohort sinovlarida yagona vosita sifatida; BCGga chidamsiz papillyar NMIBC bemorlarida yagona vosita sifatida 3-bosqich BOND-003 P kohort sinovlarida. Kompaniya, shuningdek, TURBTdan keyin o'rtacha xavfli NMIBC uchun kreto'stimogen monoterapiyasini ishlab chiqadi, bu adjuvant kreto'stimogenning xavfsizligi va samaradorligini baholash uchun 3-bosqich PIVOT-006 klinik sinovlarida; va 2-bosqich CORE-008 klinik sinovlarida yuqori xavfli NMIBC uchun kreto'stimogen monoterapiyasini ishlab chiqadi, bu yuqori xavfli NMIBC bemorlarini davolashda, shu jumladan BCGga duchor bo'lgan va BCGga duchor bo'lmagan NMIBClarni davolashda kreto'stimogenning xavfsizligi va klinik natijalarini baholash uchun. Kompaniya ilgari Cold Genesys, Inc. nomi bilan tanilgan va 2020 yil iyun oyida CG Oncology, Inc. nomini o'zgartirgan. CG Oncology, Inc. 2010 yilda tashkil etilgan va shtab-kvartirasi Kaliforniyaning Irvine shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Vijay Kasturi M.D. | Chief Medical Officer |
| Mr. Ambaw Bellete M.S. | President & COO |
| Mr. Arthur Kuan | Chairman & CEO |
| Mr. Bing Kung | Vice President of Corporate Development |
| Mr. James M. DeTore | Interim Principal Financial & Accounting Officer |
| Mr. Joshua F. Patterson | General Counsel, Chief Compliance Officer & Secretary |
| Mr. Swapnil Bhargava Ph.D. | Chief Technical Officer |
| Ms. Amy Steele |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-01-09 | 8-K | ck0001991792-20260109.htm |
| 2025-11-26 | 8-K | ck0001991792-20251122.htm |
| 2025-11-14 | 10-Q | ck0001991792-20250930.htm |
| 2025-09-09 | 8-K | ck0001991792-20250909.htm |
| 2025-09-05 | 8-K | ck0001991792-20250905.htm |
| 2025-08-08 | 8-K | ck0001991792-20250808.htm |
| 2025-07-11 | 8-K | ck0001991792-20250707.htm |
| 2025-06-06 | 8-K | ck0001991792-20250605.htm |
| 2025-05-13 | 8-K | ck0001991792-20250513.htm |
| 2025-04-28 | 8-K | ck0001991792-20250426.htm |
| Vice President of Finance & Administration |
| Ms. Sarah Connors | Vice President of Communications & Patient Advocacy |